var data={"title":"Bupropion: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bupropion: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5770?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bupropion-drug-information\" class=\"drug drug_general\">see &quot;Bupropion: Drug information&quot;</a> and <a href=\"topic.htm?path=bupropion-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bupropion: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708639\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Bupropion is not approved for use in pediatric patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143210\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aplenzin;</li>\n      <li>Buproban [DSC];</li>\n      <li>Forfivo XL;</li>\n      <li>Wellbutrin SR;</li>\n      <li>Wellbutrin XL;</li>\n      <li>Wellbutrin [DSC];</li>\n      <li>Zyban</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143211\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bupropion SR;</li>\n      <li>Mylan-Bupropion XL;</li>\n      <li>Novo-Bupropion SR;</li>\n      <li>PMS-Bupropion SR;</li>\n      <li>ratio-Bupropion SR;</li>\n      <li>Sandoz-Bupropion SR;</li>\n      <li>Wellbutrin SR;</li>\n      <li>Wellbutrin XL;</li>\n      <li>Zyban</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1002151\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidepressant, Dopamine-Reuptake Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Smoking Cessation Aid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1002188\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=bupropion-drug-information\" class=\"drug drug_general\">see &quot;Bupropion: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Bupropion is available as either hydrochloride or hydrobromide (Aplenzin) salt formulations which are not interchangeable on a mg per mg basis; dosage expressed in terms of the salt formulation. Patients must be able to swallow sustained or extended release products whole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b> Limited data available: Children &ge;6 years (Dopheide 2009; Pliszka 2007) and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release, hydrochloride salts: Initial: 3 mg/kg/<b>day</b> in 2 to 3 divided doses; maximum initial dose: 150 mg/<b>day</b>; titrate dose as needed to a maximum daily dose of 6 mg/kg/<b>day</b> or 300 mg/<b>day</b> with no single dose &gt;150 mg (Dopheide 2009; Pliszka 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained release (Wellbutrin SR) and extended release (Wellbutrin XL), hydrochloride salts: May be used in place of regular tablets, once the daily dose is titrated using the immediate release product and the titrated 12-hour dosage corresponds to a sustained release tablet (Wellbutrin SR) or the 24-hour dosage range corresponds to an extended release tablet size (Wellbutrin XL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Depression, refractory to SSRIs:</b> Limited data available; <b>Note:</b> May be most beneficial in patients with comorbid ADHD, conduct disorder, substance abuse problems or who want to quit smoking (Dopheide 2006). Treatment should be periodically evaluated at appropriate intervals to ensure lowest effective dose is used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release, hydrochloride salt: Children 8 to &le;11 years: Oral: Initial: 37.5 mg twice daily; titrate to response; usual dosage range: 100 to 400 mg/<b>day</b> (Dopheide 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained release, hydrochloride salt (Wellbutrin SR): Children &ge;11 years and Adolescents: Oral: Initial: 2 mg/kg up to 100 mg administered as a morning dose; may titrate as needed every 2 to 3 weeks using the following titration schedule: Step 2: Increase up to 3 mg/kg every morning; Step 3: Increase up to 3 mg/kg every morning and 2 mg/kg at 5 pm (17:00); Step 4: Increase up to 3 mg/kg/dose twice daily; maximum dose: 150 mg; reported mean effective dose: Morning: 2.2 mg/kg and afternoon: 1.7 mg/kg (Daviss 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release, hydrochloride salt (Wellbutrin XL): Children &ge;12 years and Adolescents: Oral: Initial: 150 mg once daily; may titrate after 2 weeks to 300 mg once daily if adequate response not achieved; dosing based on a pharmacokinetic study in eight patients with depression (Daviss 2006); doses as high as 400 mg/<b>day</b> have been reported (Dopheide 2006); may also be used once the daily dose is titrated using the immediate release product and the 24-hour dosage range corresponds to an extended release tablet size (Wellbutrin XL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Smoking cessation:</b> Limited data available: Adolescents &ge;14 years and &ge;40.5 kg: Sustained release, hydrochloride salt (Buproban, Zyban): Oral: Initial: 150 mg once daily for 3 days; increase to 150 mg twice daily; treatment should start while the patient is still smoking in order to allow drug to reach steady-state levels prior to smoking cessation; generally, patients should stop smoking during the second week of treatment; maximum daily dose: 300 mg/<b>day</b>; short-term efficacy was demonstrated in 104 adolescents who received therapy for 7 weeks with cessation counseling (Muramoto 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to allow for the detection of reemerging symptoms. Withdrawal symptoms resulting from abrupt discontinuation are unlikely because bupropion has minimal serotonergic activity (APA 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Wellbutrin XL: In patients receiving 300 mg once daily, taper dose down to 150 mg once daily for 2 weeks prior to discontinuing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching to or from an MAO inhibitor antidepressant:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat depression and initiation of bupropion.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 14 days to elapse between discontinuing bupropion and initiation of an MAO inhibitor intended to treat depression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Use with reversible MAO inhibitors (such as linezolid or IV methylene blue):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Do not initiate bupropion in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving bupropion and potential benefits outweigh potential risks, discontinue bupropion promptly and administer linezolid or IV methylene blue. Monitor for increased risk of hypertensive reactions for 2 weeks or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume bupropion 24 hours after the last dose of linezolid or IV methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Depression:</b> Oral: <b>Note:</b> Treatment should be periodically evaluated at appropriate intervals to ensure lowest effective dose is used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release, hydrochloride salt: Initial: 100 mg twice daily; after 3 days may increase to the usual dose of 100 mg 3 times daily; if no clinical improvement after several weeks, may increase to a maximum dose of 450 mg daily in 3 or 4 divided doses; do not exceed 150 mg in a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained release, hydrochloride salt: Initial: 150 mg daily in the morning; if tolerated, after 3 days, may increase to a target dose of 150 mg twice daily; if no clinical improvement after several weeks, may increase to a maximum dose of 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hydrochloride salt (Wellbutrin XL): Initial: 150 mg once daily in the morning; if tolerated, as early as day 4, may increase to 300 mg once daily (maximum dose: 300 mg/day; however, guidelines suggest up to 450 mg/day may be used [APA 2010]). <b>Note:</b> Forfivo XL may only be used after initial dose titration with other bupropion products.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hydrochloride salt (Forfivo XL): Switching from Wellbutrin immediate release, SR, or XL to Forfivo XL: Patients receiving 300 mg daily of bupropion hydrochloride for at least 2 weeks and requiring a dose increase or patients already taking 450 mg daily of bupropion hydrochloride may switch to Forfivo XL 450 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hydrobromide salt (Aplenzin): Initial: 174 mg once daily in the morning; may increase as early as day 4 of dosing to 348 mg once daily (target dose); maximum dose: 522 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Switching from hydrochloride salt formulation (eg, Wellbutrin immediate release, SR, XL, or Forfivo XL ) to hydrobromide salt formulation (Aplenzin):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bupropion hydrochloride 150 mg daily is equivalent to bupropion hydrobromide 174 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bupropion hydrochloride 300 mg daily is equivalent to bupropion hydrobromide 348 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bupropion hydrochloride 450 mg daily is equivalent to bupropion hydrobromide 522 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seasonal affective disorder (SAD):</b> Initial: 150 mg once daily (Wellbutrin XL) or 174 mg once daily (Aplenzin) in the morning; if tolerated, may increase after 1 week to 300 mg once daily (Wellbutrin XL) or 348 mg once daily (Aplenzin) in the morning.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Prophylactic treatment should be reserved for those patients with frequent depressive episodes and/or significant impairment. Initiate treatment in the autumn prior to symptom onset, and discontinue in early spring with dose tapering. Doses &gt;300 mg daily (Wellbutrin XL) or &gt;348 mg daily (Aplenzin) have not been studied in SAD (maximum: Wellbutrin XL 300 mg daily; Aplenzin 522 mg daily).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Smoking cessation (Zyban, Buproban):</b> Initial: 150 mg once daily for 3 days; increase to 150 mg twice daily; treatment should continue for 7 to 12 weeks (maximum dose: 300 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Therapy should begin at least 1 week before target quit date. Target quit dates are generally in the second week of treatment. If patient successfully quits smoking after 7 to 12 weeks, may consider ongoing maintenance therapy based on individual patient risk:benefit. Efficacy of maintenance therapy (300 mg daily) has been demonstrated for up to 6 months. Conversely, if significant progress has not been made by the seventh week of therapy, success is unlikely and treatment discontinuation should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Dosing conversion between hydrochloride salt immediate (Wellbutrin), sustained (Wellbutrin SR), and extended release (Wellbutrin XL, Forfivo XL) products:</i></b> Convert using same total daily dose (up to the maximum recommended dose for a given dosage form), but adjust frequency as indicated for sustained (twice daily) or extended (once daily) release products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to allow for the detection of reemerging symptoms. Withdrawal symptoms resulting from abrupt discontinuation are unlikely because bupropion has minimal serotonergic activity (APA 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aplenzin: In patients receiving 348 mg once daily, taper dose down to 174 mg once daily for 2 weeks prior to discontinuing</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Forfivo XL: Because the 450 mg tablet is the only available dose formulation, use another bupropion formulation for tapering the dose prior to discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Wellbutrin XL: In patients receiving 300 mg once daily, taper dose down to 150 mg once daily for 2 weeks prior to discontinuing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching to or from an MAO inhibitor antidepressant:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat depression and initiation of bupropion.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Allow 14 days to elapse between discontinuing bupropion and initiation of an MAO inhibitor intended to treat depression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Use with reversible MAO inhibitors (such as linezolid or IV methylene blue):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Do not initiate bupropion in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving bupropion and potential benefits outweigh potential risks, discontinue bupropion promptly and administer linezolid or IV methylene blue. Monitor for increased risk of hypertensive reactions for 2 weeks or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume bupropion 24 hours after the last dose of linezolid or IV methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Use with caution; manufacturer's labeling suggests a reduction in dose and/or frequency be considered but does not provide specific dosing recommendations. Aplenzin, Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban product labeling defines renal impairment as GFR &lt;90 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Forfivo XL: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate hepatic impairment (Child-Pugh score 5 or 6): Use with caution; manufacturer&rsquo;s labeling suggests a reduction in dose and/or frequency be considered but does not provide specific dosing recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Forfivo XL: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment, including severe hepatic cirrhosis: (Child-Pugh score 7 to 15): Use with extreme caution:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum doses:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aplenzin: 174 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Buproban: Severe hepatic cirrhosis: 150 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Forfivo XL: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Wellbutrin: 75 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Wellbutrin SR: 100 mg once daily or 150 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Wellbutrin XL: 150 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Zyban: 150 mg every other day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143184\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Wellbutrin: 75 mg [DSC], 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Buproban: 150 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Wellbutrin SR: 100 mg, 150 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyban: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 150 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrobromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aplenzin: 174 mg, 348 mg, 522 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Forfivo XL: 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Wellbutrin XL: 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143168\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874410\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aplenzin: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022108s014lbl.pdf#page=28&amp;token=DAta2WF+29/XSrbLCwM3Kmy9Q9zHwht4ry9t6CqvtWMbznKt8slGyUZtuEi6g3xJHUg214tN8yHrO7gOuAo2UmPEBCRFh69zPRypGakOKMMXNquVbvGeHWK6Elkeb1RU&amp;TOPIC_ID=12719\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022108s014lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Forfivo XL: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022497s004lbl.pdf#page=32&amp;token=wUAmSzuBbaPf3zVAUZbHyRQJoibJVdDtl/06yM1ORONUtqHekzOoR++PekPB8eTLBs7+Gz9KRxF/DyDjb6kWnELEekEkE0I1g2RPuscNUBfjecCNKywN5G6ou05Lnxgq&amp;TOPIC_ID=12719\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022497s004lbl.pdf#page=32</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wellbutrin: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018644s052lbl.pdf#page=31&amp;token=M0MNJsomh/6bSClg8tYgtQdmUWgI2oaMhMbJ/hmEn4ms4mHlLQ9Y3mh2CDePgI5vfloj/Hyl+Ue4VnwMNr6T6MmEkevksXyK+qYsJ7syhUnZg/wbZVmz6iHVZUiy5DwA&amp;TOPIC_ID=12719\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018644s052lbl.pdf#page=31</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wellbutrin SR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020358s059lbl.pdf#page=34&amp;token=dz5XCVrfNdhBJ9hEkwN7MHyIXlC5tBH/ODFb0kSR2a29m5Aq5lPtYhWXYeoU6WFFjWcbbgBl6q9JSkqDYeepZklV7wa3eRTwlSyO3jw51zyHJI2pbO9I+tXkpseTOeUJ&amp;TOPIC_ID=12719\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020358s059lbl.pdf#page=34</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wellbutrin XL: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021515s036lbl.pdf#page=28&amp;token=5jntS5P9Xwwj9qmPmCpMhSJGkNvRk6zi5lGMiXJ2NKAdF608pofddFbTWmFLYWYyqNjDhTi5LFYNBB/4LDZfghK/APOiv0pqR6erwwLnBoyCszNWpoZJwmoU6/aa5LyI&amp;TOPIC_ID=12719\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021515s036lbl.pdf#page=28</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zyban: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020711s045s046s047lbl.pdf#page=37&amp;token=IwD7Lgj7Y2MHgHy5RVThzV3SrrQr+ahCNnFIdKyJNBrH5Fu7syArSh1mkqrOuZKhz72CIVGcuYaQ44StLEBKKKQ9nAe/oLvVc2LXDi8gIC6u1Y4rn/gpse5cqMko2IhJ&amp;TOPIC_ID=12719\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020711s045s046s047lbl.pdf#page=37</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1002194\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be taken without regard to meals. Do not crush, chew, or divide sustained or extended release tablets (hydrochloride and hydrobromide salt formulations); swallow whole. The insoluble shell of the extended-release tablet may remain intact during GI transit and is eliminated in the feces. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Administer with at least 6 hours between successive doses; do not exceed 150 mg in a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sustained release: Typically administer 2 times daily with at least 8 hours between successive doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Administer once daily with at least 24 hours between successive doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143205\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1002152\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of major depressive disorder (Aplenzin, Forfivo XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL: FDA approved in adults), seasonal affective disorder (SAD) (Aplenzin, Wellbutrin XL: FDA approved in adults); adjunct in smoking cessation (Buproban, Zyban: FDA approved in adults); has also been used to treat ADHD</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143252\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aplenzin may be confused with Albenza, Relenza</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BuPROPion may be confused with busPIRone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Forfivo XL may be confused with Forteo</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Wellbutrin XL may be confused with Wellbutrin SR </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyban may be confused with Diovan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143249\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, chest pain, flushing, hypertension (may be severe), hypotension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormality in thinking, agitation, akathisia, anxiety, central nervous system stimulation, confusion, depression, dizziness, drowsiness, dystonia, headache, hostility, insomnia, irritability, lack of concentration, memory impairment, migraine, nervousness, pain, paresthesia, sensory disturbance, sleep disorder, twitching</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hot flash, menstrual disease, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dyspepsia, dysphagia, flatulence, increased appetite, nausea, oral mucosa ulcer, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary frequency, urinary tract infection, urinary urgency, vaginal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, dyskinesia, myalgia, neck pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory disturbance, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, epistaxis, increased cough, nasopharyngitis, pharyngitis, rhinitis, sinusitis, upper respiratory infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal accommodation, abnormal stools, akinesia, alopecia, amnesia, anaphylactoid reaction, anemia, angioedema, angle-closure glaucoma, aphasia, ataxia, atrioventricular block, cerebrovascular accident, colitis, coma, complete atrioventricular block, cystitis, deafness, delayed hypersensitivity, delirium, delusions, depersonalization, derealization, drug-induced Parkinson disease, dry eye syndrome, dysarthria, dyspareunia, dysphoria, dysuria, ecchymoses, edema, EEG pattern changes, ejaculatory disorder, erythema multiforme, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal reaction, extrasystoles, facial edema, gastric ulcer, gastroesophageal reflux disease, gastrointestinal hemorrhage, gingival hemorrhage, gingivitis, glossitis, glycosuria, gynecomastia, hallucination, hepatic injury, hepatic insufficiency, hepatitis, hirsutism, homicidal ideation, hyperglycemia, hyperkinesia, hypertonia, hypoglycemia, hypokinesia, hypomania, hyponatremia, impotence, increased intraocular pressure, increased libido, inguinal hernia, intestinal perforation, jaundice, leg cramps, leukocytosis, leukopenia, lymphadenopathy, maculopapular rash, manic behavior, menopause, muscle rigidity, myasthenia, mydriasis, myocardial infarction, myoclonus, neuralgia, neuropathy, orthostatic hypotension, painful erection, pancreatitis, pancytopenia, panic, paranoia, peripheral edema, phlebitis, pneumonia, prostatic disease, psychosis, pulmonary embolism, restlessness, rhabdomyolysis, salpingitis, sciatica, seizure (dose-related), serum sickness-like reaction, SIADH, sialorrhea, skin photosensitivity, Stevens-Johnson syndrome, stomatitis, suicidal ideation, syncope, tardive dyskinesia, thrombocytopenia, tongue edema, urinary incontinence, urinary retention, vaginitis, vasodilatation, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143192\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bupropion or any component of the formulation; seizure disorder; history of anorexia/bulimia; patients undergoing abrupt discontinuation of ethanol or sedatives, including benzodiazepines, barbiturates, or antiepileptic drugs; use of MAO inhibitors (concurrently or within 14 days of discontinuing either bupropion or the MAO inhibitor); initiation of bupropion in a patient receiving linezolid or intravenous methylene blue</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aplenzin, Forfivo XL, Wellbutrin XL: Additional contraindications: Other conditions that increase seizure risk, including arteriovenous malformation, severe head injury, severe stroke, CNS tumor, CNS infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Forfivo XL: Additional contraindications: Patients receiving other dosage forms of bupropion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concurrent use or use within 14 days of thioridazine; concurrent use with other dosage forms of bupropion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143172\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings (use in treating psychiatric disorders):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior (use in treating psychiatric disorders): <b>[US Boxed Warning]: Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors</b>, particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); <b>advise families and caregivers of the need for close observation and communication with the prescriber.</b> A medication guide concerning the use of antidepressants should be dispensed with each prescription.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS stimulation: May cause CNS stimulation (restlessness, anxiety, insomnia) or anorexia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cognitive impairment: May cause motor or cognitive impairment in some patients, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactoid/anaphylactic reactions have occurred, with symptoms of pruritus, urticaria, angioedema, and dyspnea. Serious reactions have been (rarely) reported, including erythema multiforme, Stevens-Johnson syndrome and anaphylactic shock. Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity resembling serum sickness have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: May elevate blood pressure and cause hypertension. Events have been observed in patients with or without evidence of preexisting hypertension. The risk is increased when used concomitantly with monoamine oxidase inhibitors, nicotine replacement, or other drugs that increase dopaminergic or noradrenergic activity. Assess blood pressure before treatment and monitor periodically.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May precipitate a manic, mixed, or hypomanic episode; risk is increased in patients with bipolar disorder or who have risk factors for bipolar disorder. Screen patients for a history of bipolar disorder and the presence of risk factors including a family history of bipolar disorder, suicide, or depression. <b>Bupropion is not FDA approved for bipolar depression. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric effect (use in smoking cessation): Serious neuropsychiatric events have occurred in patients taking bupropion for smoking cessation, including changes in mood (eg, depression, mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, panic, suicidal ideation, suicide attempt, and completed suicide. The majority occurred during bupropion treatment; some occurred during treatment discontinuation. A causal relationship is uncertain as depressed mood may be a symptom of nicotine withdrawal. Some cases also occurred in patients taking bupropion who continued to smoke. Neuropsychiatric effects occurred in patients with and without preexisting psychiatric disease; some patients experienced a worsening of their psychiatric illnesses. However, subsequent controlled trials in patients with or without psychiatric disorders have not identified significant differences in neuropsychiatric effects for patients taking bupropion, varenicline, nicotine patches, or placebo (Anthenelli 2016; Cinciripini 2013). Observe all patients taking bupropion for neuropsychiatric reactions. Instruct patients to stop taking bupropion and contact a health care provider if neuropsychiatric reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May cause mild pupillary dilation, which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: May cause delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion; most common in depressed patients and patients with a diagnosis of bipolar disorder. Symptoms may abate with dose reduction and/or withdrawal of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: May cause a dose-related risk of seizures. Use is contraindicated in patients with a history of seizures or certain conditions with high seizure risk (eg, history of anorexia/bulimia or patients undergoing abrupt discontinuation of ethanol, benzodiazepines, barbiturates, or antiepileptic drugs). Aplenzin, Forfivo XL, and Wellbutrin XL are also contraindicated in patients with certain conditions with high seizure risk (eg, arteriovenous malformation, severe head injury, severe stroke, CNS tumor, and CNS infection). Use caution with concurrent use of antipsychotics, antidepressants, theophylline, systemic corticosteroids, stimulants (including cocaine), anorexiants, or hypoglycemic agents, or with excessive use of ethanol, benzodiazepines, sedative/hypnotics, or opioids. Use with caution in seizure-potentiating metabolic disorders (hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia). The dose-dependent risk of seizures may be reduced by gradual dose increases and by not exceeding the maximum daily dose. Do not coadminister with other bupropion-containing formulations; Forfivo XL is contraindicated in patients receiving other dosage forms of bupropion. Permanently discontinue if seizure occurs during therapy. Chewing, crushing, injecting, or dividing long-acting products may increase seizure risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sexual dysfunction: The incidence of sexual dysfunction with bupropion is generally lower than with SSRIs (Clayton 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight loss: May cause weight loss; use caution in patients where weight loss is not desirable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD (off-label use): All children diagnosed with ADHD who may be candidates for stimulant medications should have a thorough cardiovascular assessment to identify risk factors for sudden cardiac death prior to initiation of drug therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, history of hypertension, or coronary artery disease; treatment-emergent hypertension (including some severe cases) has been reported, both with bupropion alone and in combination with nicotine transdermal systems.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; consider a reduction in dose and/or frequency; Forfivo XL is not recommended in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; consider a reduction in dose and/or frequency; Forfivo XL is not recommended in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be at greater risk of drug accumulation during chronic dosing. Consider a reduction in dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release tablet: Insoluble tablet shell may remain intact and be visible in the stool.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse: Using doses higher than prescribed may result in increased motor activity, agitation/excitement and euphoria. Inhalation of crushed tablets or injection of dissolved bupropion has been reported, some resulting in seizures and death.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electroconvulsive therapy (ECT): May increase the risks associated with ECT; consider discontinuing, when possible, prior to ECT treatment (APA 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820019\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as bupropion, should have a thorough cardiovascular assessment prior to initiation of therapy. These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). This assessment should include a combination of thorough medical history, family history, and physical examination. An ECG is not mandatory but should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143235\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate), OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143177\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12719&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents With Seizure Threshold Lowering Potential: BuPROPion may enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment. Management: Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the adverse/toxic effect of BuPROPion. Specifically, both drugs have the potential to decrease the seizure threshold, possibly increasing the risk for seizures.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of BuPROPion.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): May enhance the adverse/toxic effect of BuPROPion.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: BuPROPion may enhance the adverse/toxic effect of Citalopram. BuPROPion may increase the serum concentration of Citalopram.  Management: Initiate citalopram at the lower end of the normal dose range in patients receiving bupropion, and consider limiting the maximum citalopram adult dose to 20 mg/day during concomitant bupropion treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Inducers (Moderate): May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Inhibitors (Weak): May increase the serum concentration of BuPROPion.<b> Exceptions: </b>Prasugrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: BuPROPion may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May decrease the serum concentration of BuPROPion.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of BuPROPion. Management: Monitor for decreased response to bupropion in patients treated with efavirenz.  Increased bupropion doses may be required.  Avoid the use of naltrexone/bupropion for weight management in patients receiving efavirenz.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: BuPROPion may enhance the adverse/toxic effect of FLUoxetine. BuPROPion may increase the serum concentration of FLUoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: BuPROPion may enhance the adverse/toxic effect of FluvoxaMINE. BuPROPion may increase the serum concentration of FluvoxaMINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: BuPROPion may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May decrease the serum concentration of BuPROPion.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of BuPROPion. Concentrations of the active metabolite, hydroxybupropion, may also be decreased. Management: Monitor bupropion response closely. Significant bupropion dose adjustments may be necessary to maintain adequate response.  Avoid the use of naltrexone/bupropion for weight management in patients receiving lopinavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorcaserin: BuPROPion may enhance the serotonergic effect of Lorcaserin. This could result in serotonin syndrome.  Management: Seek alternatives to this combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of BuPROPion.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OCT2 Substrates: BuPROPion may increase the serum concentration of OCT2 Substrates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: BuPROPion may enhance the adverse/toxic effect of PARoxetine. BuPROPion may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported. Management: Monitor for decreased bupropion effects.  Significant bupropion dose adjustments may be necessary to maintain adequate response.  Avoid the use of naltrexone/bupropion for weight management in patients receiving ritonavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: BuPROPion may decrease the metabolism of Tricyclic Antidepressants.  Management: Seek alternatives when possible. Monitor patients receiving these combinations closely for increased serum concentrations (when testing is available) and toxic effects of the tricyclic antidepressant.<b> Exceptions: </b>Amoxapine; Protriptyline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vortioxetine: BuPROPion may enhance the adverse/toxic effect of Vortioxetine. BuPROPion may increase the serum concentration of Vortioxetine.  Management: The vortioxetine dose should be reduced by 50% when used together with bupropion.  Following cessation of bupropion, the vortioxetine dose should be returned to the normal level.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143179\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062314\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Bupropion and its metabolites were found to cross the placenta in in vitro studies (Earhart 2012). An increased risk of congenital malformations has not been observed following maternal use of bupropion during pregnancy; however, data specific to cardiovascular malformations is inconsistent. The long-term effects on development and behavior have not been studied.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that antidepressant therapy during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (ACOG 2008; APA 2010; Yonkers 2009). There is insufficient information related to the use of bupropion to recommend use in pregnancy (ACOG 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1002196\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure (baseline and periodically especially when used in conjunction with nicotine transdermal replacement); renal and hepatic function,  body weight. Monitor mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks, tics; periodically monitor for symptom resolution</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD:</b> Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1002178\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic levels (trough, 12 hours after last dose): 50 to 100 ng/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143171\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Aminoketone antidepressant structurally different from all other marketed antidepressants; like other antidepressants the mechanism of bupropion's activity is not fully understood. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine, and does not inhibit monoamine oxidase or the reuptake of serotonin. Metabolite inhibits the reuptake of norepinephrine. The primary mechanism of action is thought to be dopaminergic and/or noradrenergic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143191\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 1 to 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: 1 to 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~20 to 47 L/kg (Laizure 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 84% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP2B6 to hydroxybupropion; non-CYP-mediated metabolism to  erythrohydrobupropion and threohydrobupropion. Metabolite activity ranges from 20% to 50% potency of bupropion. Bupropion also undergoes oxidation to form the glycine conjugate of meta-chlorobenzoic acid, the major urinary metabolite. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Distribution: 3 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elimination: ~21 hours after chronic dosing (range: 12 to 30 hours); Metabolites (after a single dose): Hydroxybupropion: 20 &plusmn; 5 hours; Erythrohydrobupropion: 33 &plusmn; 10 hours; Threohydrobupropion: 37 &plusmn; 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release (Aplenzin): 21 &plusmn; 7 hours; Metabolites: Hydroxybupropion: 24 &plusmn; 5 hours; Erythrohydrobupropion: 31 &plusmn; 8 hours; Threohydrobupropion: 51 &plusmn; 9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bupropion: Immediate release: Within 2 hours; Sustained release: Within 3 hours; Extended release: ~5 hours (Forfivo XL: 5 hours [fasting]; 12 hours [fed])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metabolite: Hydroxybupropion: Immediate release: ~3 hours; Extended release, sustained release: ~6 to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (87%, primarily as metabolites); feces (10%, primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143194\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (BuPROPion HCl ER (Smoking Det) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $116.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (BuPROPion HCl ER (SR) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $168.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $193.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $215.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Wellbutrin SR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $484.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $518.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $963.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Zyban Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $297.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Aplenzin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">174 mg (30): $1,561.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">348 mg (30): $2,058.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">522 mg (30): $4,685.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (BuPROPion HCl ER (XL) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $143.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $172.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Forfivo XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (30): $513.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Wellbutrin XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $1,542.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $2,035.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (BuPROPion HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $79.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $106.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F143196\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Betetrim (TW);</li>\n      <li>Bupep SR (IN);</li>\n      <li>Buprotrin (TW);</li>\n      <li>Buxon (CL);</li>\n      <li>Deppreo (VN);</li>\n      <li>Elontril (EE, ES, HU, LT, RO, SK);</li>\n      <li>Funnix (TW);</li>\n      <li>Le Fu Ting (CN);</li>\n      <li>Nicopion (KR);</li>\n      <li>Nicostop (VN);</li>\n      <li>Odranal (AR, CO);</li>\n      <li>Prewell (TW);</li>\n      <li>Prexaton (AU);</li>\n      <li>Quomen (TH);</li>\n      <li>Wellbutrin (MX, PE, PY, TW, UA, VE);</li>\n      <li>Wellbutrin Retard (IS, SK);</li>\n      <li>Wellbutrin SR (AR, BB, BM, BS, CL, CR, DO, EC, GT, HK, HN, HU, JM, KR, LV, NI, PA, SG, SV, UY);</li>\n      <li>Wellbutrin XL (BB, BH, BM, BS, CO, CR, DO, EC, GT, HK, HN, JM, KR, KW, NI, PA, PE, QA, SA, SV, TH, TW);</li>\n      <li>Wellbutrin XR (CY, HR, IL, LU, MT, SI, TR, UA);</li>\n      <li>Yue Ting (CN);</li>\n      <li>Zyban (AE, AT, BB, BE, BG, BM, BR, BS, BZ, CH, CY, CZ, DE, DK, FI, FR, GB, GR, GY, IE, IL, IN, IS, IT, JM, MT, NL, NO, NZ, PL, PR, PT, RO, SA, SE, SI, SR, TR, TT, UA);</li>\n      <li>Zyban LP (FR);</li>\n      <li>Zyban SR (BH, KW, QA, SG);</li>\n      <li>Zyban Sustained Release (AU);</li>\n      <li>Zylexx SR (PK);</li>\n      <li>Zyntabac (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins--Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG, &quot;Committee Opinion No. 471: Smoking Cessation During Pregnancy,&quot; <i>Obstet Gynecol</i>, 2010, 116(5):1241-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/20966731/pubmed\" target=\"_blank\" id=\"20966731\">20966731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroon.com/index.php?s=43&amp;item=422.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aplenzin (bupropion) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/22299006/pubmed\" target=\"_blank\" id=\"22299006\">22299006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chaudron LH and Schoenecker CJ, &quot;Bupropion and Breastfeeding: A Case of a Possible Infant Seizure,&quot; <i>J Clin Psychiatry</i>, 2004, 65(6):881-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/15291673/pubmed\" target=\"_blank\" id=\"15291673\">15291673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson J, &ldquo;Seizures and Bupropion: A Review,&rdquo; <i>J Clin Psychiatry</i>, 1989, 50(7):256-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/2500425/pubmed\" target=\"_blank\" id=\"2500425\">2500425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis MF, Miller HS, and Nolan PE Jr, &quot;Bupropion Levels in Breast Milk for 4 Mother-Infant Pairs: More Answers to Lingering Questions,&quot; <i>J Clin Psychiatry</i>, 2009, 70(2):297-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/19265649/pubmed\" target=\"_blank\" id=\"19265649\">19265649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daviss WB, Bentivoglio P, Racusin R, et al, &quot;Bupropion Sustained Release in Adolescents With Comorbid Attention-Deficit/Hyperactivity Disorder and Depression,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2001, 40(3):307-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/11288772/pubmed\" target=\"_blank\" id=\"11288772\">11288772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daviss WB, Perel JM, Birmaher B, et al, &quot;Steady-State Clinical Pharmacokinetics of Bupropion Extended-Release in Youths,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(12):1503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/17135996/pubmed\" target=\"_blank\" id=\"17135996\">17135996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daviss WB, Perel JM, Rudolph GR, et al. Steady-state pharmacokinetics of bupropion SR in juvenile patients. <i>J Am Acad Child Adolesc Psychiatry</i>. 2005;44(4):349-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/15782082/pubmed\" target=\"_blank\" id=\"15782082\">15782082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA, &quot;Recognizing and Treating Depression in Children and Adolescents,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(3):233-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/16434782/pubmed\" target=\"_blank\" id=\"16434782\">16434782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Earhart AD, Patrikeeva S, Wang X, et al, &quot;Transplacental Transfer and Metabolism of Bupropion,&quot; <i>J Matern Fetal Neonatal Med</i>, 2010, 23(5):409-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/19658039/pubmed\" target=\"_blank\" id=\"19658039\">19658039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forfivo XL [prescribing information]. Austin, TX: Edgemont Pharm; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haas JS, Kaplan CP, Barenboim D, et al, &quot;Bupropion in Breast Milk: An Exposure Assessment for Potential Treatment to Prevent Post-Partum Tobacco Use,&quot; <i>Tob Control</i>, 2004, 13(1):52-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/14985597/pubmed\" target=\"_blank\" id=\"14985597\">14985597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hack S, &quot;Pediatric Bupropion-Induced Serum Sickness Like Reaction,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2004, 14(3):478-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/15650506/pubmed\" target=\"_blank\" id=\"15650506\">15650506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hale TW, Kendall-Tackett K, Cong Z, et al, &quot;Discontinuation Syndrome in Newborns Whose Mothers Took Antidepressants While Pregnant or Breastfeeding,&quot; <i>Breastfeed Med</i>, 2010, 5(6):283-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/20807106/pubmed\" target=\"_blank\" id=\"20807106\">20807106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jennison TA, Brown P, Crossett J, et al, &ldquo;A High-Performance Liquid Chromatographic Method for Quantitating Bupropion in Human Plasma or Serum,&rdquo; <i>J Anal Toxicol</i>, 1995, 19(2):69-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/7769789/pubmed\" target=\"_blank\" id=\"7769789\">7769789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leverich GS, Altshuler LL, Frye MA, et al, &ldquo;Risk of Switch in Mood Polarity to Hypomania or Mania in Patients with Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers,&rdquo; <i>Am J Psychiatry</i>, 2006, 163(2):232-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/16449476/pubmed\" target=\"_blank\" id=\"16449476\">16449476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntyre RS, Mancini DA, McCann S, et al, &ldquo;Topiramate Versus Bupropion SR When Added to Mood Stabilizer Therapy for the Depressive Phase of Bipolar Disorder: A Preliminary Single-Blind Study,&rdquo; <i>Bipolar Disord</i>, 2002, 4(3):207-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/12180276/pubmed\" target=\"_blank\" id=\"12180276\">12180276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muramoto ML, Leischow SJ, Sherrill D, et al, &quot;Randomized, Double-Blind, Placebo-Controlled Ttrial of 2 Dosages of Sustained-Release Bupropion for Adolescent Smoking Cessation,&quot; <i>Arch Pediatr Adolesc Med</i>, 2007, 161(11):1068-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/17984409/pubmed\" target=\"_blank\" id=\"17984409\">17984409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24732787\"></a>Neuman G, Colantonio D, Delaney S, Szynkaruk M, Ito S. Bupropion and escitalopram during lactation. <i>Ann Pharmacother</i>. 2014;48(7):928-931.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/24732787/pubmed\" target=\"_blank\" id=\"24732787\">24732787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo; <i>Am J Health Syst Pharm</i>, 2004, 61(9):899-912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/15156966/pubmed\" target=\"_blank\" id=\"15156966\">15156966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.<i> J Am Acad Child Adolesc Psychiatry</i>. 2007 Jul;46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka SR, Crismon ML, Hughes CW, et al, &quot;The Texas Children&rsquo;s Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of ADHD,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2006, 45(6):642-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/16721314/pubmed\" target=\"_blank\" id=\"16721314\">16721314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riggs PD, Leon SL, Mikulich SK, et al, &ldquo;An Open Trial of Bupropion for ADHD in Adolescents With Substance Use Disorders and Conduct Disorder,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 1998, 37(12):1271-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/9847499/pubmed\" target=\"_blank\" id=\"9847499\">9847499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/26204124/pubmed\" target=\"_blank\" id=\"26204124\">26204124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turpeinen M, Koivuviita N, Tolonen A, et al, &quot;Effect of Renal Impairment on the Pharmacokinetics of Bupropion and Its Metabolites,&quot; <i>Br J Clin Pharmacol</i>, 2007, 64(2):165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/17335546/pubmed\" target=\"_blank\" id=\"17335546\">17335546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Wyck FJ, Manberg PJ, Miller LL, et al, &ldquo;Overview of Clinically Significant Adverse Reactions to Bupropion,&rdquo; <i>J Clin Psychiatry</i>, 1983, 44(5 Pt 2):191-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/6406456/pubmed\" target=\"_blank\" id=\"6406456\">6406456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson C, et al, &quot;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2008, 117(18):2407-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner KD, &quot;Pharmacotherapy for Major Depression in Children and Adolescents,&quot; <i>Prog Neuropsychopharmacol Biol Psychiatry</i>, 2005, 29(5):819-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/15908090/pubmed\" target=\"_blank\" id=\"15908090\">15908090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wellbutrin (bupropion) [prescribing information. Research Triangle Park, NC: GlaxoSmithKline; Decembe 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al, &quot;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&quot; <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bupropion-pediatric-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12719 Version 277.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708639\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F143210\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F143211\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1002151\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1002188\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F143184\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F143168\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874410\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1002194\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F143205\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1002152\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F143252\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F143249\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F143192\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F143172\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820019\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F143235\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F143177\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F143179\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3062314\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1002196\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1002178\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F143171\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F143191\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F143194\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F143196\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12719|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bupropion-drug-information\" class=\"drug drug_general\">Bupropion: Drug information</a></li><li><a href=\"topic.htm?path=bupropion-patient-drug-information\" class=\"drug drug_patient\">Bupropion: Patient drug information</a></li></ul></div></div>","javascript":null}